Traws Pharma Inc. announced the completion of enrollment in its Phase 2 clinical study evaluating ratutrelvir, an investigational oral Mpro/3CL protease inhibitor, in comparison to PAXLOVID® in patients with mild-to-moderate COVID-19. The study also includes a single arm for patients ineligible to receive PAXLOVID®. According to the company, ongoing clinical results indicate ratutrelvir has demonstrated a differentiated profile versus PAXLOVID®, with observations of fewer adverse events, absence of viral rebounds, and faster time to sustained symptom resolution. These findings have also been observed in PAXLOVID®-ineligible patients. Final results have not yet been presented. Additionally, Traws Pharma provided an update on its tivoxavir marboxil program, indicating that a new compressed tablet formulation may offer 28-day prophylactic protection against a broad range of seasonal and pandemic-potential influenza variants. A human influenza prophylaxis challenge study is scheduled for June 2026, following a planned bridging study in healthy volunteers to confirm extended drug exposure. Results from the challenge study will determine progression to registration studies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9642133-en) on January 26, 2026, and is solely responsible for the information contained therein.
Comments